SecurityGSUM / Gridsum Holding Inc. (398132100)
Institutional Owners41 (2 N-Q Owners)
Institutional Shares60,462,155 (ex. N-Q)
Institutional Value$ 40,241,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

GSUM / Gridsum Holding Inc. Institutional Ownership

Gridsum Holding Inc. (NASDAQ:GSUM) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 60,462,155 shares. Largest shareholders include Steamboat Ventures Asia, L.P., Qi Guosheng, Futurex Innovation Spc, Moon Capital Management Lp, Light Street Capital Management, Llc, Guofa Yu, Wells Fargo & Company/mn, FIL Ltd, Capital Research Global Investors, and Federated Investors Inc /pa/.
Gridsum Holding Inc. (NASDAQ:GSUM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/gsum"><img src="https://images.fintel.io/us-gsum-so.png" alt="GSUM / Gridsum Holding Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-02 13F-HR Global X Management CO LLC 4,648 38
2018-05-09 13F-HR FEDERATED INVESTORS INC /PA/ 300,000 300,000 0.00 2,745 2,451 -10.71
2018-05-15 13F-HR D. E. Shaw & Co., Inc. 0 11,293 0 92
2018-03-27 N-Q Federated Equity Funds (see advisory)
2018-04-25 13F-HR PICTET ASSET MANAGEMENT LTD 90,868 0 -100.00 831 0 -100.00
2018-05-15 13F-HR UBS Group AG 1,210 383 -68.35 11 3 -72.73
2018-02-13 SC 13G/A Steamboat Ventures Asia, L.P. 3,470,052 34,700,529 900.00
2018-04-18 13F-HR REGIONS FINANCIAL CORP 100 100 0.00 1 1 0.00
2018-04-06 SC 13G LIGHT STREET CAPITAL MANAGEMENT, LLC 1,752,657
2018-05-15 13F-HR DEUTSCHE BANK AG\ 573 20,611 3,497.03 5 168 3,260.00
2018-02-14 13F-HR 12 West Capital Management LP 220,088 0 -100.00 2,267 0 -100.00
2018-05-14 13F-HR FIL Ltd 1,209,297 1,042,643 -13.78 11,065 8,518 -23.02
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 62,682 512
2018-02-12 SC 13G/A Qi Guosheng 9,044,462 9,179,878 1.50
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 300 0 -100.00 3 0 -100.00
2018-04-05 13F-HR WHALEROCK POINT PARTNERS, LLC 68,400 55,135 -19.39 626 450 -28.12
2018-05-15 13F-HR Capital Research Global Investors 1,005,000 1,005,000 0.00 9,196 8,211 -10.71
2018-05-15 13F-HR INDUS CAPITAL PARTNERS, LLC 115,797 279,323 141.22 1,060 2,282 115.28
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 89,309 228,157 155.47 817 1,864 128.15
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 10,907 0 -100.00 100 0 -100.00
2018-05-15 13F-HR CREDIT SUISSE AG/ 47,971 391
2018-05-14 13F-HR MORGAN STANLEY 4,800 4,500 -6.25 44 37 -15.91
2018-02-12 SC 13G/A Guofa Yu 1,393,038 1,393,038 0.00
2018-03-29 N-Q Powershares Exchange Traded Fund Trust (see advisory)
2018-05-10 13F-HR JP Morgan Chase & Co 346 0 -100.00 3 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1,265,927 1,282,627 1.32 11,584 10,479 -9.54
2018-05-15 13F-HR PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO 5,000 4,200 -16.00 46 34 -26.09
2018-02-12 13F-HR MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC 467,447 0 -100.00 4,815 0 -100.00
2018-05-15 13F-HR WOLVERINE TRADING, LLC Call 33,200 271
2018-01-10 13F-HR NEW SILK ROAD INVESTMENT PTE LTD 53,600 0 -100.00 552 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 25 109 336.00 0 1
2018-05-15 13F-HR ASHFORD CAPITAL MANAGEMENT INC 10,000 82
2018-05-04 13F-HR Quantitative Systematic Strategies LLC 11,360 11,024 -2.96 104 90 -13.46
2018-05-08 13F-HR Athos Capital Ltd 83,538 160,461 92.08 764 1,311 71.60
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 14,705 120
2018-05-15 13F-HR WOLVERINE TRADING, LLC Put 34,100 279
2018-05-15 13F-HR SOROS FUND MANAGEMENT LLC 150,000 0 -100.00 1,373 0 -100.00
2018-05-15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 26,959 220
2018-05-15 13F-HR BARCLAYS PLC 61,103 499
2018-05-11 13F-HR Cutler Group LP Call 1,800 0
2018-04-26 13F-HR SIMPLEX TRADING, LLC 9,725 79
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 10,282 0 -100.00 94 0 -100.00
2018-02-14 13F-HR DRIEHAUS CAPITAL MANAGEMENT LLC 742,827 0 -100.00 7,651 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 3,271 0 -100.00 30 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 54,300 444
2018-05-15 13F-HR ELLINGTON MANAGEMENT GROUP LLC 22,400 0 -100.00 205 0 -100.00
2018-05-01 SC 13G MOON CAPITAL MANAGEMENT LP 2,360,859
2018-05-14 13F-HR Herald Investment Management Ltd 100,000 100,000 0.00 915 815 -10.93
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 68,995 0 -100.00 631 0 -100.00
2018-02-13 13F-HR/A Centerstar Asset Management, Llc 39
2018-04-25 13F-HR QUENTEC ASSET MANAGEMENT LLC 760,562 0 -100.00 6,959 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 80,364 79,143 -1.52 735 647 -11.97
2018-05-15 13F-HR WOLVERINE TRADING, LLC 26,205 214
2018-05-15 13F-HR Invesco Ltd. 28,582 29,834 4.38 262 244 -6.87
2018-05-11 13F-HR Cutler Group LP 2,000 16
2018-05-15 13F-HR STATE STREET CORP 35,300 28,800 -18.41 323 235 -27.24
2018-05-15 SC 13D Futurex Innovation Spc 6,153,846
2018-05-09 13F-HR NORTHERN TRUST CORP 15,019 12,007 -20.05 137 98 -28.47

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( GSUM / Gridsum Holding Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

BRIEF-Gridsum Announces Proposed Investment From FutureX Capital

2018-05-01 reuters
* GRIDSUM HOLDING - ON APRIL 30, 2018, ENTERED CONVERTIBLE NOTE PURCHASE AGREEMENT WITH FUTUREX INNOVATION SPC (0-4)

Enterprise Artificial Intelligence Could Make Gridsum Holding The Swing Trade Of 2018

2018-01-29 seekingalpha
GSUM believes it is currently the technology market leader in the China enterprise-focused AI space with a global best-of-breed enterprise-AI engine. (253-4)

CUSIP: 398132100